| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Counted by filing, the last 12 months brought no open-market purchases and 9 sales by 4 insiders worth about $1.1M. The 12 months before that brought 2 open-market purchases by 2 insiders worth about $1.5M and 2 sales by 2 insiders worth about $179K.
All 9 sales in the last 12 months were made under a Rule 10b5-1 trading plan set up in advance.
The largest open-market purchase in the last two years was 47,500 shares by Rachel McMinn (Chief Executive Officer) at an average $20.40 on November 22, 2024, about $969K. Twelve months later NGNE was down 1%.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CEO | 1.35M | $35.87M | - | |
| CFO | 84.0K | $2.24M | - | |
| Other | 30.5K | $813.4K | - | |
| Other | 12.5K | $332.6K | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jul 7, 2026 | Christine Mikail Cvijic46 | President and CFO | Sell10b5-1 | 4,800 | $36.12 | $173,375.40 | -5.4% | -28.1% | - | |
| Jul 2, 2026 | Christine Mikail Cvijic46 | President and CFO | Sell10b5-1 | 4,800 | $34.71 | $166,586.36 | -5.1% | -21.3% | - | |
| May 6, 2026 | Christine Mikail Cvijic46 | President and CFO | Sell10b5-1 | 9,600 | $31.25 | $300,043.20 | -9.3% | +6.4% | - | |
| Mar 26, 2026 | Julie Jordan | Chief Medical Officer | Sell10b5-1 | 828 | $21.89 | $18,127.57 | -6.2% | +40.4% | - | |
| Mar 26, 2026 | Rachel McMinn | Chief Executive Officer | Sell10b5-1 | 3,352 | $22.07 | $73,995.06 | -0.2% | +40.4% | - | |
| Mar 26, 2026 | Christine Mikail Cvijic46 | President and CFO | Sell10b5-1 | 2,558 | $21.62 | $55,315.98 | -2.4% | +40.4% | - | |
| Mar 13, 2026 | Stuart Cobb | Chief Scientific Officer | Sell10b5-1 | 6,797 | $20.81 | $141,445.87 | -18.2% | +34.8% | - | |
| Mar 13, 2026 | Christine Mikail Cvijic46 | President and CFO | Sell10b5-1 | 4,045 | $20.81 | $84,176.31 | -3.7% | +34.8% | - | |
| Feb 27, 2026 | Christine Mikail Cvijic46 | President and CFO | Sell10b5-1 | 4,800 | $25.11 | $120,526.08 | -4.2% | +17.1% | - | |
| May 14, 2025 | Stuart Cobb | Chief Scientific Officer | Sell10b5-1 | 6,797 | $15.15 | $103,003.10 | -24.6% | +26.3% | +105.5% |